MB076

Names

[ Name ]:
MB076

Biological Activity

[Description]:

MB076 is a novel heterocyclic triazole with improved plasma stability. MB076 inhibits seven different Class C Acinetobacter-derived cephalosporinases (ADCs) β-lactamase variants with Ki values ＜ 1 μM. MB076 acts synergistically in combination with multiple cephalosporins to restore pBCSK(−) susceptibility[1].

[Related Catalog]:

Research Areas >> Others

Signaling Pathways >> Others >> Others

[Target]

Ki Target: ADC-7, ADC-30, ADC-162, ADC-33, ADC-219, ADC-212[1] Ki: 0.21±0.016 μM (ADC-7), 0.058±0.005μM (ADC-30), 0.79±0.039μM (ADC-162), 0.10±0.004μM (ADC-33), 0.11±0.019 (ADC-219), 0.61±0.038μM (ADC-212)[1]

[References]

[1]. Rachel A. Powers, et al. Synthesis of a Novel Boronic Acid Transition State Inhibitor, MB076: A Heterocyclic Triazole Effectively Inhibits Acinetobacter-Derived Cephalosporinase Variants with an Expanded-Substrate Spectrum. J Med Chem. 2023 Jul 13; 66(13): 8510–8525.

Chemical & Physical Properties

[ Molecular Formula ]:
C₉H₁₂BN₇O₅S₂

[ Molecular Weight ]:
373.18

Related Compounds

The content on this webpage is sourced from various professional data sources. If you have any questions or concerns regarding the content, please feel free to contact service1@chemsrc.com.